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Available online 30 September 2016Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-
degeneration are major causes of blindness. Fenoﬁbrate treatment in type 2 diabetes patients reduces progres-
sion of diabetic retinopathy independent of its peroxisome proliferator-activated receptor (PPAR)α agonist
lipid lowering effect. The mechanism is unknown. Fenoﬁbrate binds to and inhibits cytochrome P450
epoxygenase (CYP)2C with higher afﬁnity than to PPARα. CYP2C metabolizes ω-3 long-chain polyunsaturated
fatty acids (LCPUFAs). Whileω-3 LCPUFA products from other metabolizing pathways decrease retinal and cho-
roidal neovascularization, CYP2C products of both ω-3 and ω-6 LCPUFAs promote angiogenesis. We hypothe-
sized that fenoﬁbrate inhibits retinopathy by reducing CYP2C ω-3 LCPUFA (and ω-6 LCPUFA) pro-angiogenic
metabolites. Fenoﬁbrate reduced retinal and choroidal neovascularization in PPARα-/-mice and augmented ω-
3 LCPUFA protection via CYP2C inhibition. Fenoﬁbrate suppressed retinal and choroidal neovascularization in
mice overexpressing human CYP2C8 in endothelial cells and reduced plasma levels of the pro-angiogenic ω-3
LCPUFA CYP2C8 product, 19,20-epoxydocosapentaenoic acid. 19,20-epoxydocosapentaenoic acid reversed
fenoﬁbrate-induced suppression of angiogenesis ex vivo and suppression of endothelial cell functions in vitro.
In summary fenoﬁbrate suppressed retinal and choroidal neovascularization via CYP2C inhibition as well as by
acting as an agonist of PPARα. Fenoﬁbrate augmented the overall protective effects of ω-3 LCPUFAs on
neovascular eye diseases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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acids1. Introduction
Pathological ocular neovascularization causes vision loss in retinopa-
thy of prematurity in children, in proliferative diabetic retinopathy in
adults, and in age-related macular degeneration (AMD) in the elderly
population (Hellstrom et al., 2013; Antonetti et al., 2012; Gibson, 2012).
Neovascularization can be suppressed with anti-angiogenic agents, such
as anti-vascular endothelial growth factor (VEGF) molecules (Cheungd macular degeneration; CNV,
es; CYP, cytochrome P450
ydocosapentaenoic acid; EET,
id; HRMEC, human retinal
yunsaturated fatty acids; LOX,
osphate buffered saline; PPAR,
r endothelial growth factor.
ton, MA 02115, United States.
.H. Smith).
. This is an open access article underet al., 2012; Liu et al., 2015). However, anti-VEGF therapy can also sup-
press normal vessel growth and neuronal survival (Suzuki et al., 2011;
Sato et al., 2012). Therefore, therapeutic agents inhibiting ocular neovas-
cularization with fewer adverse effects are desirable.
Fenoﬁbrate reduces serum cholesterol and triglyceride levels in pa-
tients at risk for cardiovascular disease such as those with diabetes
mellitus (Keech et al., 2005). Fenoﬁbrate also reduces the risk of prolifer-
ative diabetic retinopathy by 35–40% as noted in two intervention trials
of N20,000 patients with type 2 diabetes mellitus, the Fenoﬁbrate Inter-
vention and Event Lowering inDiabetes (FIELD) and theAction to Control
Cardiovascular Risk in Diabetes (ACCORD) studies (Keech et al., 2007;
Group et al., 2010). The MacuFen study also suggests that fenoﬁbrate
treatment decreases volume of diabetic macular edema (Massin et al.,
2014). The mechanism underlying the protective effect of fenoﬁbrate
on diabetic retinopathy is independent of its ability to initiate a peroxi-
some proliferator-activated receptor (PPAR) α-mediated lipid lowering
effect (Bogdanov et al., 2015; Simo et al., 2015). There are no clinicalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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although fenoﬁbrate has been shown to have a potent anti-apoptotic ef-
fect in the ischemic retina, to suppress ischemia-induced endothelial pro-
genitor cell mobilization and homing, and to inhibit angiogenesis in vivo
and in vitro (Moran et al., 2014; Wang et al., 2014; Varet et al., 2003).
Fenoﬁbrate is a well-known PPARα agonist, but an in vitro assess-
ment of 209 frequently prescribed drugs and related xenobiotics sug-
gests that it is also a potent inhibitor of cytochrome P450 epoxygenase
(CYP)2C (Walsky et al., 2005). The afﬁnity of fenoﬁbrate to CYP2C is
N10 times higher (EC50 = 2.39 ± 0.4 μM) than to PPARα (EC50 =
30 μM) (Schoonjans et al., 1996).We hypothesized that the suppressive
effects of fenoﬁbrate on retinopathy might be mediated through sup-
pression of CYP2C pro-angiogenic metabolites. Important CYP2C sub-
strates with respect to retinopathy are ω-3 and ω-6 long-chain
polyunsaturated fatty acids (LCPUFAs). Themajorω-3 andω-6 LCPUFAs
found in the eye are respectively docosahexaenoic acid (DHA, C22:6ω-
3) and arachidonic acid (AA, C20:4ω-6) (Sangiovanni et al., 2009a).
DHA is present in the retina at a higher concentration (20%) than in
any other tissues (SanGiovanni and Chew, 2005; Sapieha et al., 2012).
LCPUFAs (and their biologically active pro and anti-angiogenic me-
tabolites) inﬂuence the development of neovascular eye diseases
(SanGiovanni and Chew, 2005; Sapieha et al., 2012; Stahl et al., 2011;
Fu et al., 2016). Dietary intake of ω-3 versus ω-6 LCPUFAs is associated
with suppression of pathological retinal angiogenesis in animal models
for retinopathy of prematurity, proliferative diabetic retinopathy and
AMD (Connor et al., 2007; Gong et al., 2015) with the implication that
the sum total of ω-3 LCPUFA metabolites are anti-angiogenic. Bioactive
ω-3 and ω-6 LCPUFA metabolites are produced by three major enzyme
systems: the cyclooxygenases (COX), lipoxygenases (LOX) and CYPs. Al-
though cyclooxygenase and lipoxygenaseω-6 LCPUFA-derivedmetabo-
lites are generally pro-angiogenic,ω-3 LCPUFA-derived cyclooxygenase
analogues are generally anti-angiogenic including prostaglandin E3,
which inhibits endothelial tubule formation (Szymczak et al., 2008),
and the 5-lipoxygenase metabolite 4-hydroxydocosahexaenoic acid
mediates much of the anti-retinopathy effect of ω-3 LCPUFA diet in
mouse retinopathy. 4-Hydroxydocosahexaenoic acid reduces retinal in-
ﬂammation and inhibits endothelial cell functions by activating PPARγ
(Sapieha et al., 2011). CYP2Cmetabolizes LCPUFAs to biologically active,
pro-angiogenic epoxides (Tsao et al., 2001). While ω-3 LCPUFA prod-
ucts from the other metabolic pathways inhibit angiogenesis, CYP2C
metabolites derived from ω-3 (and ω-6) LCPUFAs, such as 19,20-
epoxydocosapentaenoic acid (EDP) and 14,15-epoxyeicosatrienoic
acid (EET), promote retinal neovascularization(Shao et al., 2014), sug-
gesting that CYP2C inhibition would be beneﬁt neovascular eye dis-
eases. We hypothesized that the inhibitory effect of fenoﬁbrate on
retinopathy (seen in the FIELD and ACCORD studies) is due to CYP2C in-
hibition and reduction in levels of pro-angiogenic CYP2C metabolites.
Current mouse models for diabetic retinopathy do not develop neo-
vascularization. To evaluate fenoﬁbrate effects on neovascular eye dis-
eases we employed the mouse model of oxygen-induced retinopathy
(OIR), which has reproducible and quantiﬁable retinal neovasculariza-
tion similar to proliferative diabetic retinopathy as well as the laser-in-
duced choroidal neovascularization (CNV) model of neovascular
AMD(Smith et al., 1994; Gong et al., 2015). Fenoﬁbrate suppressed
both retinal and choroidal neovascularization in associationwith lower-
ing the plasma levels of CYP2Cmetabolites and enhanced the protective
effects of ω-3 LCPUFAs on pathological choroidal and retinal angiogen-
esis. This study suggested that fenoﬁbrate suppressed neovasculariza-
tion through both PPARα agonist activity and CYP2C inhibition.
2. Materials and Methods
2.1. Mice
Tie2-driven CYP2C8 overexpressing transgenic mice were on a
C57BL/6 background (Edin et al., 2011). Wild-type C57BL/6 mice werepurchased from the Jackson Laboratory (000664, Bar Harbor, ME). For
dietary experiments, the ω-6 LCPUFA AA and the ω-3 LCPUFAs DHA
and eicosapentaenoic acid (EPA) were obtained from DSM Nutritional
Products (TE Heerlen, Netherlands) and integrated into the rodent
feed at Research Diets (New Brunswick, NJ) (Connor et al., 2007; Shao
et al., 2014). The raw materials (TS00002988, DSM) were analyzed to
conﬁrm composition and the absence of peroxides, dioxin, benzopyrene
or heavy metal contaminants (EPA1T1615.07/111001). The mice were
fed a deﬁned rodent diet with 10% (wt/wt) safﬂower oil containing ei-
ther 2% ω-6 LCPUFA (AA) and no ω-3 LCPUFAs (DHA and EPA), or 2%
ω-3 LCPUFAs and no ω-6 LCPUFA from postnatal day (P) 1 to P17 for
the mouse model of OIR or from 7 days before laser photocoagulation
for the laser-induced CNV model. All animal experiments complied
with the Animal Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines, were carried out in accordance with the National Institutes
of Health guide for the care and use of Laboratory animals (NIH Publica-
tions No. 8023, revised 1978), and were approved by the Boston
Children's Hospital Animal Care and Use Committee.
2.2. Oxygen-induced Retinopathy
The mouse OIR model was used as described (Smith et al., 1994;
Stahl et al., 2009; Connor et al., 2009; Stahl et al., 2010). Brieﬂy to induce
retinal neovascularization, mouse pups and their nursing mother were
exposed to 75 ± 3% oxygen from P7 to P12. For the higher dose
fenoﬁbrate (F6020, Sigma-Aldrich, St. Louis, MO) treatment (100 mg/
kg/day) fenoﬁbrate was dissolved in corn oil (C8267, Sigma-Aldrich)
to make 100mg/ml solution and pure corn oil was used as vehicle con-
trol. For the lower dose treatment (10 mg/kg/day), fenoﬁbrate was dis-
solved in 10% dimethyl sulfoxide (DMSO, D2650, Sigma-Aldrich) to
make a 10 mg/ml solution and 10% DMSO was used as vehicle control.
After return to room air, mice were orally gavaged with fenoﬁbrate
(100 or 10 mg/kg) or vehicle control daily from P12 to P16. At P17,
eyes were enucleated immediately after euthanasia and ﬁxed in 4%
paraformaldehyde (P6148, Sigma-Aldrich) in phosphate buffered saline
(PBS, 10010-023, Thermo Fisher Scientiﬁc, Waltham, MA) for 1 h at
room temperature. Retinas were then dissected and stained overnight
with Alexa Fluor 594 conjugated isolectin GS-IB4 (10 μg/ml, I21413,
Thermo Fisher Scientiﬁc) at room temperature. After washing with
PBS, retinas were mounted ontomicroscope slides (12-550-15, Thermo
Fisher Scientiﬁc) with photoreceptor side down and embedded in
SlowFade antifade mounting medium (S2828, Thermo Fisher Scientif-
ic). Retinal images were taken using a ﬂuorescence microscope
(AxioObserver.Z1, Carl Zeiss Microscopy, Jena, Germany) with image
software (AxioVision 4.6.3.0, Carl Zeiss Microscopy). Retinal neovascu-
larization was analyzed with the SWIFT_NV macro plugin in ImageJ
(Connor et al., 2009).
2.3. Laser-induced Choroidal Neovascularization
The mouse model of laser-induced CNV was used as reported(Poor
et al., 2014; Gong et al., 2015). Laser photocoagulation was induced
using an image-guided laser system (Micron IV, Phoenix Research Lab-
oratories, Pleasanton, CA) in mice ages 6–8 weeks. Four laser burns at
equal distance from the optic nerve head were generated in each eye
by a green Argon laser pulsewith awavelength of 532 nm, a ﬁxed diam-
eter of 50 μm, duration of 70ms, and power level of 240mW. Eyeswere
enucleated 7 days after laser photocoagulation and ﬁxed with 4% para-
formaldehyde in PBS for 1 h at room temperature. The posterior eye
cups consisting of the retinal pigment epithelium/choroid/sclera were
dissected and permeabilized with 0.1% Triton X-100 (×100, Thermo
Fisher Scientiﬁc) in PBS for 1 h at room temperature. The CNV lesions
were stained overnight with isolectin GS-IB4 (10 μg/ml) at room tem-
perature. After washingwith PBS, the posterior eye cups weremounted
with the scleral side down. Fluorescent imageswere taken and the areas
of lesions were quantiﬁed in a masked fashion.
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Plasma levels of CYP2C8 products from ω-3 and ω-6 LCPUFAs
were determined by liquid chromatography tandemmass spectroscopy
(LC/MS/MS) after liquid/liquid extraction with ethyl acetate as previ-
ously described (Edin et al., 2011; Shao et al., 2014). Online liquid chro-
matography of extracted samples was performed with an Agilent 1200
Series capillary high performance liquid chromatography (Agilent
Technologies, Santa Clara, CA). Separation was achieved using a
Phenomenex Luna column (5 m, 150 × 1 mm, Phenomenex, Torrance,
CA). Analysis was performed on an MDS Sciex API 3000 equipped
with a TurboIonSpray source (Applied Biosystems, Foster City, CA).
2.5. Aortic Ring Assay
Aortae from 3 to 8 week old C57BL/6 J mice were dissected and cut
into ~1mmthick rings(Baker et al., 2012), embedded into growth factor
reduced Matrigel (354230, Corning, Corning, New York), and grown in
complete classic medium (4Z0-500, Cell Systems, Kirkland, WA) sup-
plemented with CultureBoost (4CB-500, Cell Systems) and Penicillin-
Streptomycin (Thermo Fisher) at 37 °C with 5% CO2. Fenoﬁbric acid
(10 μM, 90,568, Sigma-Aldrich), DHA (30 μM, 90310, Cayman Chemical,
Ann Arbor, Michigan) or 19,20-EDP (1 μM, 10175, Cayman Chemical)
was added to the culture medium 48 h later, and mediumwas changed
every other day. Phase contrast photos of individual explants were
taken 6 days after plating and the sprouting area was quantiﬁed with
ImageJ with a semi-automatedmacro plugin for quantiﬁcation of vessel
sprouts.
2.6. Choroidal Sprouting Assay
Retinal pigment epithelium/choroid/sclera complex (also referred to
as “choroid explant”) from3week old C57BL/6 Jmicewas dissected and
cut into approximately 1 mm × 1 mm pieces (Shao et al., 2013). The
choroid explants were embedded into growth factor reduced Matrigel,
cultured and imaged with similar methods used for the aortic ring
assay described above.
2.7. Tubule Formation Assay
Human retinal microvascular endothelial cells (HRMECs, ACBRI 181,
Cell system) were cultured in endothelial cell growth medium (EGM-2
MV, cc-3202, Lonza, Basel, Switzerland) and used from passage 5 to 8.
Cells were seeded onto plates pre-coated with growth factor reduced
Matrigel at a density of 2 × 105 cells/ml, and incubated in EGM-2 MV
supplemented with fenoﬁbric acid (10 μM), 19,20-EDP (1 μM), DHA
(30 μM) or corresponding vehicle controls at 37 °C with 5% CO2 for
6 h. Phase contrast photoswere taken, and the tubule formationwas an-
alyzed with Angiogenesis Analyzer for ImageJ.
2.8. Wound Healing Assay
HRMECwere grown to conﬂuence on plates pre-coated with gelatin
(0.5 μg/ml, G9391, Sigma-Aldrich). After treatment with mitomycin C
(10 μg/ml, Sigma-Aldrich) for 20 min at 37 °C, monolayers were
washed, scratched with a pipet tip and incubated in EGM-2 MV at
37 °C for 24 h. Phase contrast photos were taken, and cell migration
was quantiﬁed by measuring the width of the cell-free zone (distance
between the edges of the injured monolayer) at 5 distinct positions
(Gong et al., 2013; He et al., 2016). All assays were performed in
triplicate.
2.9. Qualitative Real-time Polymerase Chain Reaction
Total RNA was extracted from retinas or HRMECs using RNeasy Kit
(74106, Qiagen, Hilden, Germany), and reverse transcribed usingrandom hexamers and SuperScript III Reverse Transcriptase (Thermo
Fisher) according to the manufacturer's instructions(Yang et al., 2011;
Yang et al., 2013). Quantitative analysis of gene expression was deter-
mined using an ABI Prism 7700 Sequence Detection System (Applied
BioSystems) and the SYBR Green Master Mix kit (KK4600, Kapa
Biosystems, Wilmington, MA)(He et al., 2014) with primers listed
below: CYP2C8 (F: 5′-TGTGGTCCTGGTGCTGTG, R: 5′-ATATTGGGGAATT
GCCTCTT), Acox1 (F: 5′- GAGCAGCAGGAGCGTTTCTT, R: 5′- CAGGACTA
TCGCATGATTGGAAG), Pdk4 (F: 5′- ACAGACATCATAATGTGGTCCCT, R:
5′- GGTCGATACTTCCAATGTGGC), ACOX1 (F: 5′- ACTCGCAGCCAGCGTTA
TG, R: 5′- AGGGTCAGCGATGCCAAAC), PDK4 (F: 5′-GGAGCATTTCTCGCG
CTACA, R: 5′-ACAGGCAATTCTTGTCGCAAA), and Cyclophilin A (F: 5′-AGG
TGGAGAGCACCAAGACAGA, R: 5′-TGCCGGAGTCGACAATGAT). Each tar-
get gene cDNA copy number was normalized to the housekeeping gene
Cyclophilin A using comparative CT (ΔΔCT)method and related to control
group.
2.10. Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM).
Student's t-test was used to compare between 2 groups of samples.
For multiple comparisons with additional interventions, two-way
ANOVA followed by Tukey's post hoc test was performed using Prism
6 (Graph-Pad, San Diego, CA). The criterion for signiﬁcance was set at
a probability of ≤0.05.
3. Results
3.1. Fenoﬁbrate Reduced Ocular Neovascularization via a PPARα-indepen-
dent Pathway
To determine if fenoﬁbrate suppressed pathological choroidal and
retinal angiogenesis through PPARα alone, both wild-type C57BL/6
and Pparα knockout mice were orally gavaged with fenoﬁbrate at
100 μg/g/day or corn oil as vehicle control, and subjected to both OIR
and laser-induced CNV. Fenoﬁbrate inhibited retinal neovascularization
by 33% (P=5.0× 10−10) and CNVby 40% (P=1.9× 10−7) inwild-type
mice. In Pparα knockout mice daily intake of fenoﬁbrate inhibited reti-
nal and choroidal neovascularization by 18% (P = 0.027) and 25%
(P = 3.5 × 10−8) respectively (Fig. 1a–d), suggesting that in addition
to the PPARα pathway, other pathways are involved in the regulation
of pathological ocular angiogenesis by fenoﬁbrate. The mRNA levels of
two PPARα target genes, Acox1 and Pdk4, were not induced by
fenoﬁbrate in the Pparα knockout retina, suggesting that fenoﬁbrate
did not act through PPARα activation (Fig. 1e&f). These results sug-
gested that fenoﬁbrate suppressed pathological ocular angiogenesis
through PPARα-independent as well as PPARα-dependent pathways.
3.2. Fenoﬁbrate Suppressed Ocular Neovascularization via CYP2C8
Inhibition
To determine if fenoﬁbrate suppressed choroidal and retinal neovas-
cularization via CYP2C8 inhibition we used a low dose to primarily in-
hibit CYP2C activity with minimal PPARα activation (Fig. 2a). To
determine the dose at which fenoﬁbrate mainly functions through the
CYP2C pathway, Tie2-driven human CYP2C8 overexpressing transgenic
mice and their wild-type littermates were orally gavaged with
fenoﬁbrate at several low doses. We found that 10 μg/g/day, 1/10 of
the standard human dose, decreased the plasma levels of the DHA-
derived CYP2C8 product, 19,20-EDP, by 40% (P = 0.018) in wild-type
and 24% (P= 0.019) in CYP2C8 overexpressing mice (Fig. 2b), but had
no effect on CYP2C expression or on mRNA levels of PPARα target
genes Acox1 and Pdk4 (Fig. 2c–f). The levels of the COX and LOXmetabo-
lites, prostaglandin E2 and 5-hydroxyeicosatetraenoic acid respectively,
were unchanged suggesting no effect on the COX and LOX metabolizing
pathways (Supplemental Table 1). Daily intake of fenoﬁbrate at this low
Fig. 1. Fenoﬁbrate suppressed retinal and choridal neovascularization in Pparα knockout mice. Wild-type (WT) C57BL/6 and Pparα knockout (KO) mice subjected to OIR (a, scale bar,
1 mm) or laser-induced CNV (b, scale bar, 500 μm; ON, optic nerve) were orally gavaged with fenoﬁbrate (100 μg/g/day) or corn oil as vehicle control from P12 to P16 for OIR or for
7 days after laser photocoagulation. Retinal and choroidal whole-mount vessels were stained with isolectin GS-IB4 at P17 or 7 days after laser photocoagulation respectively.
Fenoﬁbrate reduced retinal (c, n = 10 mice/group) neovascularization (NV, white arrows) and laser-induced CNV lesion area (d, n = 17–23 mice/group) in both WT and Pparα KO
mice. Retinal mRNA levels of Acox1 (e) and Pdk4 (f) were increased in WT and Pparα KO mice, normalized to cyclophilin A and related to WT vehicle control group. n= 6 mice/group.
* P b 0.05; *** P b 0.001; n. s., not signiﬁcant.
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duced by CYP2C8 overexpression by 29% (P=0.021) and 36% (P=1.2 ×
10−9) respectively (Fig. 3). These results conﬁrmed that fenoﬁbrate sup-
pressed pathological ocular angiogenesis through a PPARα-independent
pathway implicated to be CYP2C8 inhibition.
3.3. Fenoﬁbrate Enhanced the Protective Effects of ω-3 LCPUFAs on Ocular
Neovascularization
To test the hypothesis that fenoﬁbrate, as a potent inhibitor of
CYP2C, increases the protective effects of ω-3 LCPUFAs on pathological
ocular angiogenesis, C57BL/6 mice on a deﬁned isocaloric diet enriched
with eitherω-6 orω-3 LCPUFAswere orally gavagedwith fenoﬁbrate or
vehicle control and P7 pups subjected to OIR and 6–8 week old mice
subjected to laser-induced CNV. OIR pups of mothers fed with ω-3 ver-
sus ω-6 LCPUFA enriched diets reduced retinal neovascularization at
P17 by 25% (P = 0.023) (Fig. 4a,b). Laser-induced CNV lesion areas
were reduced by 24% (P = 2.3 × 10−4) at 7 days after laserphotocoagulation in mice fed with a ω-3 versus ω-6 LCPUFA diet.
Fenoﬁbrate increased the protective effect of ω-3 LCPUFAs on retinal
and choroidal neovascularization by 12% (P = 0.031) and 23% (P =
2.2 × 10−7) respectively (Fig. 4c&d). Fenoﬁbrate-treated animals in
the ω-6 LCPUFA dietary group showed similar effects as animals in the
ω-3 LCPUFA dietary group that were not treated with fenoﬁbrate.
These results indicated that fenoﬁbrate enhanced ω-3 LCPUFA protec-
tion on retinal and choroidal neovascularization.
3.4. 19,20-EDP but not DHA Reversed Inhibition of ex vivo Angiogenesis by
Fenoﬁbric Acid
To examine whether fenoﬁbrate reduced neovascularization via
CYP2C inhibition and decreased levels of its DHAmetabolites, we inves-
tigated the effects of fenoﬁbric acid, the biologically active derivative of
fenoﬁbrate, on angiogenesis in ex vivo tissue explants. In an aortic ring
angiogenic assay, fenoﬁbric acid inhibited aortic ring sprouting by 41%
(P = 0.0057), and the CYP2C DHA product, 19,20-EDP, reversed
Fig. 2. Fenoﬁbrate at a low dose inhibited CYP2C8 activity without PPARα activation. (a) Fenoﬁbrate (F) has different effects on PPARα and CYP2C pathways at different doses due to their
different afﬁnity to fenoﬁbrate. (b) Tie2-driven CYP2C8 transgenic (Tg) and wild-type (WT) littermate mice were orally gavaged with fenoﬁbrate (10 μg/g/day) or 10% DMSO as vehicle
control for 5 days. Fenoﬁbrate at the lowdose reversed the induction of 19,20-EDP plasma levels in CYP2C8 Tgmice. n=10mice/group, * P b 0.05. ThemRNA levels of CYP2C8 (c), Cyp2C29
(d), Acox1 (e) and Pdk4 (f) were not affected by fenoﬁbrate at the low dose in both the WT and CYP2C8 Tg retina. n = 6 mice/group, n. s., not signiﬁcant.
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(Fig. 4a,c). In the choroidal sprouting assay, similar results were ob-
served. Fenoﬁbric acid decreased the sprouting area from choroidal ex-
plants by 51% (P = 0.0053), and 19,20-EDP reversed its inhibitory
effects by 37% (P=0.0035) (Fig. 4b,d). The addition of DHA, the precur-
sor of not only CYP2C-derived 19,20-EDP but also of COX and LOX de-
rived anti-angiogenic metabolites, further potentiated the anti-
angiogenic effect of fenoﬁbrate acid on the aortic ring and choroidal ex-
plant sprouting (Fig. 5). Co-treatment with fenoﬁbric acid and DHA led
to 78% (P = 2.4 × 10−4) and 41% (P = 0.031) reduction in sprouting
area from aorta and choroid versus 62% (P = 0.0049) and 32% (P =
0.030) reduction with fenoﬁbric acid alone and 43% (P = 9.6 × 10−5)
and 13% (P=0.042) reductionwith DHA alone (Fig. 6). These data sug-
gested that fenoﬁbric acid inhibited angiogenesis ex vivo via CYP2C in-
hibition resulting in decreased levels of CYP2C DHA pro-angiogenic
products including 19,20-EDP.
3.5. 19,20-EDP but not DHA Reversed the Inhibition of Endothelial Cell
Functions by Fenoﬁbric Acid
To clarify the speciﬁc cell type and behavior of the anti-angiogenic
effects of fenoﬁbric acid in ocular neovascularization, we examined
fenoﬁbrate's effects on endothelial cell tubule formation and migration
in vitro using HRMECs. Fenoﬁbric acid suppressed tubule formation
compared with cells treated with vehicle control, resulting in fewer
tube junctions (Fig. 7a,c). In addition, fenoﬁbric acid suppressed
HRMEC migration in a wound healing scratch assay (Fig. 7b,d). 19,20-
EDP rescued the suppression of HRMEC tubule formation andmigration
by fenoﬁbric acid (Fig. 7). However, DHA did not reverse the inhibitionof endothelial cell tubule formation or migration by fenoﬁbric acid, but
further augmented the inhibitory effects of fenoﬁbric acid (Fig. 8). These
results indicated that fenoﬁbric acid impaired endothelial cell functions
via CYP2C inhibition and theDHAmetabolites of CYP2C could reverse its
inhibition.
4. Discussion
Fenoﬁbrate has been found in interventional clinical studies (FIELD,
ACCORD and MacuFen) to reduce the rates of progression of sight-
threatening diabetic retinopathy and the volume of macular edema
(Keech et al., 2007; Group et al., 2010;Massin et al., 2014). The anti-ret-
inopathy effects appear to be independent of a fenoﬁbrate-driven acti-
vation of PPARα and subsequent lipid lowering effect(Keech et al.,
2007;Wonget al., 2012; Yu and Lyons, 2013).We found that fenoﬁbrate
inhibited neovascularization in Pparα knockoutmice through inhibition
of CYP2C to decrease CYP2C-derived ω-3 LCPUFA pro-angiogenic me-
tabolites as well as via PPARα activation.
The fenoﬁbrate dose that we used in mice in this study (100 mg/kg/
day) (Hu et al., 2013) is comparable to that used in the FIELD and AC-
CORD clinical trials for lipid lowering effects and induced the expression
of PPARα target genes, such as Acox1 and Pdk4, in the retina. Because
the index of human equivalent dose to mice is 0.081 and absorption
after oral gavage in rodents is 25–50%(Reagan-Shaw et al., 2008), the
corresponding human dose is 2–4 mg/kg/day which is comparable to
the dose used in the FIELD (200 mg/60 kg/day or ~3.3 mg/kg/day) and
the ACCORD (160 mg/60 kg/day or ~2.7 mg/kg/day) studies (Keech et
al., 2005; Chew et al., 2007), suggesting that PPARα activation might
contribute to the beneﬁcial effects of fenoﬁbrate on retinopathy
Fig. 3. Fenoﬁbrate at a low dose suppressed both retinal and choroidal neovascularization in mice overexpressing CYP2C8. Tie2-driven CYP2C8 overexpression transgenic (Tg) and wild-
type (WT) littermatemicewere subjected to OIR (a, scale bar, 1mm)or laser-inducedCNV(b, scale bar, 500 μm;ON, optic nerve). Themicewere orally gavagedwith fenoﬁbrate (10 μg/g/day)
or 10% DMSO as vehicle control fromP12 to P16 for OIR or for 7 days after laser photocoagulation respectively. Retinal and choroidal whole-mount vessels were stainedwith isolectin GS-IB4 at
P17or 7days after laser photocoagulation respectively. Fenoﬁbrate at the lowerdose suppressed the inductionof retinal (c) neovascularization (NV,white arrows) and laser-inducedCNV lesion
area (d) in CYP2C8 Tg mice. n = 10–12 mice/group. * P b 0.05; *** P b 0.001.
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to CYP2C is N10 times higher than to PPARα(Walsky et al., 2005;
Schoonjans et al., 1996). We found that oral gavage of fenoﬁbrate at
one tenth the dose (10mg/kg/day) inmice decreased the plasma levels
of LCPUFA products metabolized by CYP2C including 19,20-EDP and
14,15-EET, but had no measurable effect on PPARα target gene mRNA
expression in the retina, suggesting that in humans, inhibition of
CYP2C activity by fenoﬁbrate might also contribute to its protective ef-
fects on pathological ocular angiogenesis in these two large-scale clini-
cal trials.
Fenoﬁbrate is pharmacologically inactive and with ingestion un-
dergoes rapid hydrolysis of the ester bond to form the active metabolite
fenoﬁbric acid (Wang et al., 2014). Fenoﬁbrate inhibits angiogenesis in
vivo and in vitro by decreasing basic ﬁbroblast growth factor-induced
Akt activation and cytokine-induced vascular cell adhesion molecule 1
expression in endothelial cells through PPARα activation (Varet et al.,
2003; Marx et al., 1999). Fenoﬁbrate also affects retinal endothelial
cells in a PPARα-independent manner. For example, fenoﬁbrate regu-
lates the survival of HRMECs, but pretreatmentwith the PPARα antago-
nist MK 886 fails to alter this effect. Another selective agonist of PPARα,
WY-14643, has no discernible effect on HRMEC survival (Kim et al.,
2007). We also found that another PPARα antagonist GW6471 failed
to alter the inhibitory effects of fenoﬁbric acid on angiogenesis ex vivo
and in vitro (Supplemental Fig. 1 & 2). In human umbilical vein endo-
thelial cells, fenoﬁbrate increases 5′ adenosinemonophosphate-activat-
ed protein kinase phosphorylation, but neither PPARα activator
bezaﬁbrate nor WY-14,643 has the same effect (Murakami et al.,
2006). Studies of PPARα-independent mechanisms of action of
fenoﬁbrate and identiﬁcation of the master regulators of PPARα-inde-
pendent effects are still limited. Our results suggested CYP2C as apotential PPARα-independent mediator of fenoﬁbrate action in endo-
thelial cells.
CYP2C comprises amajor group of CYPmixed-function epoxygenases
involved in the oxidation of both xenobiotic and endogenous compounds
(Edin et al., 2011). Many drugs, including fenoﬁbrate, are metabolized by
CYP2C enzymes (Walsky et al., 2005). In addition to being a CYP2C sub-
strate, fenoﬁbrate is also reported to regulate the expression of some
CYP2C isoforms in the kidney (Muller et al., 2004). CYP2C8, together
with CYP2C9, is one of the most abundant CYP2C enzymes in human
tissues and their epoxygenase activity modulates both physiological
and pathological angiogenesis (Tsao et al., 2001). CYP2C8 homologues
in mice, such as Cyp2C29 and Cyp2C55, are expressed in macrophages
and endothelial cells in the eye, and they are induced by OIR (Nelson et
al., 2004; Shao et al., 2014). Fenoﬁbrate is identiﬁed by in vitro screening
as a potent suppressor of CYP2C8, aswell as CYP2C9(Walsky et al., 2005).
In our studies, fenoﬁbrate reduced retinal and choroidal neovasculariza-
tion not only in Tie2-driven human CYP2C8 transgenic mice but also in
wild-type mice, which suggested that fenoﬁbrate inhibited not only ex-
ogenous human CYP2C8 but also endogenous mouse Cyp2C activity.
We also showed that fenoﬁbrate had no effect on CYP2C8 and Cyp2C29
mRNA levels, indicating that its protective effects on ocular neovascular-
ization were mediated by CYP2C activity but not expression.
Dietary intake ofω-3 versusω-6 LCPUFAs reduces pathological ocular
angiogenesis (Connor et al., 2007; Koto et al., 2007; Moghaddam-Taaheri
et al., 2011). Theω-3 LCPUFA, DHA, inhibits angiogenesis ex vivo and en-
dothelial functions in vitro,which is consistentwith previous publications
and likely related to its metabolites produced through cyclooxygenase
and lipoxygenase, rather than through CYP pathways (Sapieha et al.,
2011; Szymczak et al., 2008; Gong et al., 2016). The different effects re-
ported on CNV of an exogenously delivered single ω-3 LCPUFA CYP
Fig. 4. Fenoﬁbrate augmented the protective effects ofω-3 LCPUFAs against retinal and choridal neovascularization. Wild-type C57BL/6 mice fed with aω-6 orω-3 LCPUFA enriched diet
were subjected to OIR (a, scale bar, 1mm) or laser-induced CNV (b, scale bar, 500 μm;ON, optic nerve). Themicewere orally gavagedwith fenoﬁbrate (100 μg/g/day) or corn oil as vehicle
control from P12 to P16 for OIR or for 7 days after laser photocoagulation. Retinal and choroidal whole-mount vessels were stained with isolectin GS-IB4 at P17 or 7 days after laser
photocoagulation respectively. Fenoﬁbrate augmented the protective effects of ω-3 LCPUFAs on retinal (c) neovascularization (NV, white arrows) and laser-induced CNV lesion area
(d). n = 10 mice/group. * P b 0.05; ** P b 0.01; *** P b 0.001.
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ogenous administration rather than an evaluation of the sum total of all
metabolites after inhibition of CYP2C activity(Yanai et al., 2014; Gong et
al., 2016). DHA supplementation did not reverse the angiogenesis inhibi-
tory effects of fenoﬁbrate, but further increased the suppression of angio-
genesis, suggesting that DHA on balance was metabolized by other
enzymes into anti-angiogenicmetabolites and that fenoﬁbrate functioned
downstreamofDHA. In contrast to themodest increase in anti-angiogenic
effects of DHA on the inhibition of angiogenesis with fenoﬁbrate, addition
of CYP2C products derived fromDHA, such as 19,20-EDP, reversed the in-
hibitory effects of fenoﬁbrate on angiogenesis ex vivo and endothelial cell
functions in vitro, suggesting that fenoﬁbrate functioned upstream of
CYP2C products. Our results suggested that inhibition of CYP2C activity
by fenoﬁbrate augmented the protective effect ofω-3 LCPUFAs on patho-
logical ocular angiogenesis.
Fenoﬁbrate reversed the induction of retinal and choroidal neovas-
cularization in CYP2C8 overexpressing mice fed either a ω-3 or ω-6
LCPUFA enriched diet, suggesting that CYP2C products derived from
both ω-3 and ω-6 LCPUFAs were pro-angiogenic in the retina and cho-
roid. A previous study shows that 19,20-EDP inhibits tumor growth and
human umbilical vein endothelial cell functions in vitro (Zhang et al.,
2013). The different expression pattern of growth factors andmetabolic
enzymes in the retina and in tumormight contribute to the different ef-
fects of the CYP2C metabolite observed, indicating a tissue-speciﬁc role
of 19,20-EDP. Knowledge on the molecular mechanism or regulation of
angiogenesis and endothelial cell behaviors by CYP2Cmetabolites, such
as EDPs and EETs, is still limited. Previous studies suggest that 11,12-EET
induces angiogenesis in human umbilical vein endothelial cells through
the phosphatidylinositol-3-OHkinase pathwaymediating phosphoryla-
tion of FOXO factors which cause decreased expression of the cyclindependent kinase inhibitor p27Kip1, and that 14,15-EET promotes angio-
genesis in a mouse wound healing model through VEGF induction
(Potente et al., 2003; Sander et al., 2013). A recent study indicates that
11,12-EET promotes hematopoietic stem and progenitor cell speciﬁca-
tion by increasing activator protein 1 and runx1 transcription through
the phosphatidylinositol-3-OH kinase pathway(Li et al., 2015), which
has also been implicated in advanced AMD by our previous work
(SanGiovanni et al., 2009b). More research on the direct target and
downstream pathways of CYP2C metabolites is needed.
In summary we found that fenoﬁbrate inhibited pathological
ocular angiogenesis by suppressing CYP2C activity that led to de-
creased levels of CYP2C pro-angiogenic products from both ω-6
and ω-3 LCPUFAs. Dietary intake of ω-3 LCPUFAs helped prevent
retinal and choroidal neovascularization and CYP2C inhibition by
fenoﬁbrate enhanced the protective effects of ω-3 LCPUFAs against
pathological angiogenesis in the eye. Combination therapy of dietary
ω-3 LCPUFA supplementation with fenoﬁbrate may be a promising
approach to prevent incidence or progression of abnormal retinal
and choroidal neovascularization.
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